Brief: Ryvu Therapeutics Signs EUR 3.8 Mln Deal For JASPIS-01 Clinical Trial

Ryvu Therapeutics SA

21/10/2024 06:38

Oct 21 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * THE COMPANY SAID ON FRIDAY IT HAD SIGNED AN AGREEMENT WITH
US-BASED SYNEOS HEALTH, AND SYNEOS HEALTH UK TO COOPERATIVELY
PERFORM OF PHASE II OF JASPIS-01 CLINICAL TRIAL
    * THE TRIALS CONCERN PATIENTS WITH RELAPSED REFRACTORY
DIFFUSE
LARGE B-CELL LYMPHOMA (DLBCL)
    * THE START OF TRIAL IS PLANNED FOR Q4 AND WILL OCCUR IN
POLAND
AND BE GRADUALLY EXPANDED WITHIN EU AND OUTSIDE OF EU
    * TOTAL COST OF AGREEMENT IS SET AT 3.8 MILLION EUROS AND
WILL BE
COVERED IN ITS ENTIRETY BY THE COMPANY'S PARTNER MENARINI GROUP

        
 Source text for Workspace:  urn:newsml:reuters.com:*:nEM5c09qCa
 Further company coverage:  RVU.WA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))